Aardvark Therapeutics, Inc. 8K

Aardvark Therapeutics reported Q2 2026 results, highlighted ongoing FDA discussions and data assessment for its ARD-101 PWS program under clinical hold, and stated its cash runway extends into late 2027.

Aardvark Therapeutics, Inc. reported its unaudited financial results for the quarter ended June 30, 2026, and provided business updates indicating that it is assessing unblinded Phase 3 HERO and OLE trial data for ARD-101 in Prader-Willi Syndrome during the third quarter of 2026 while remaining in active discussions with the FDA to resolve a full clinical hold on the ARD-101 IND imposed in May 2026. The company previously terminated both the HERO and OLE trials in June 2026 and does not intend to resume them as previously designed. For the second quarter of 2026, Aardvark recorded a net loss of $14.4 million on R&D expenses of $10.5 million and G&A expenses of $4.6 million, with the decrease in R&D driven primarily by reduced external CMC, clinical, and toxicology costs following the voluntary pause of all clinical trials and the subsequent clinical hold, partially offset by higher personnel costs before a June 2026 workforce reduction. The company ended the quarter with $73.9 million in cash, cash equivalents, and short-term investments and stated that, based on its current operating plans, this capital is expected to fund operations into late 2027.

Filing Facts

CIK

1774857

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-344978

Alert Tier

7